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We previously reported that tumour-associated caveolin-1 is a potential biomarker in renal cell carcinoma (RCC), whose
overexpression predicts metastasis following surgical resection for clinically confined disease. Much attention has recently focused on
the AKT/mTOR pathway in a number of malignancies, including RCC. Since caveolin-1 and the AKT/mTOR signalling cascade are
independently shown to be important regulators of tumour angiogenesis, we hypothesised that caveolin-1 interacts with the AKT/
mTOR pathway to drive disease progression and metastasis in RCC. The aims of this study were to determine (i) the expression
status of the activated AKT/mTOR pathway components (phosphorylated forms) in RCC and (ii) their prognostic value when
combined with caveolin-1. Immunohistochemistry for caveolin-1, pAKT, pmTOR, pS6 and p4E-BP1 was performed on tissue
microarrays from 174 clinically confined RCCs. Significantly decreased mean disease-free survival was observed when caveolin-1 was
coexpressed with either pAKT (2.95 vs 6.14 years), pmTOR (3.17 vs 6.28 years), pS6 (1.45 vs 6.62 years) or p4E-BP1 (2.07 vs 6.09
years) than when neither or any one single biomarker was expressed alone. On multivariate analysis, the covariate of ‘caveolin-1/AKT’
(neither alone were influential covariates) was a significant influential indicator of poor disease-free survival with a hazard ratio of 2.13
(95% CI: 1.15–3.92), higher than that for vascular invasion. Tumours that coexpressed caveolin-1 and activated mTOR components
were more likely to be larger, higher grade and to show vascular invasion. Our results provide the first clinical evidence that caveolin-1
cooperates with an activated AKT/mTOR pathway in cancer and may play an important role in disease progression. We conclude
that evaluation of the ‘caveolin-1/AKT/mTOR axis’ in primary kidney tumours will identify subsets of RCC patients who require
greater postoperative surveillance and more intensive treatment.
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During the last 20 years, the incidence of renal cell carcinoma
(RCC) in the developed world has progressively increased
accounting for approximately 3% of cancers and 2% of all
cancer-related deaths (Ljungberg et al, 2007). Renal cell carcinoma
represents a heterogeneous group of neoplasms of varying clinical
course even in patients with seemingly similar pathology. Two-
thirds of all RCC patients have clinically localised disease at initial
presentation and will undergo full surgical resection of the primary
tumour. Despite this intervention, up to 40% will later develop
distant metastasis for which patient outcomes are poor (Ljungberg
et al, 1999; Janzen et al, 2003).
The high relapse rates for patients with localised disease
following nephrectomy indicate the presence of undetected
micrometastasis at the time of surgery (Rodriguez and Sexton,
2006). An enormous challenge is the assessment of the risk of
disease recurrence. Although stage, grade, presence of vascular
invasion and histological subtype are the currently accepted
prognostic indicators, none affords the accuracy required for
confident prognostication and therapy selection (Rodriguez and
Sexton, 2006; Shuch et al, 2006; Park and Eisen, 2007). Additional
prognostic indices such as those offered by predictive biomarkers
are needed for precise identification of patients at high risk of
disease progression and those who will benefit from novel
molecular-targeted therapies that have started to emerge for the
treatment of RCC (Gore et al, 2007; Nelson et al, 2007).
Many cellular processes are regulated by AKT including
proliferation, mobility, neovascularisation and survival (Samuels
and Ericson, 2006). At the plasma membrane, AKT is activated
through phosphorylation by phosphoinositide 3-kinase (PI3K) at
The308 and Ser473, residues within the AKT kinase domain and
the COOH-terminal regulatory tail, respectively (Cheng et al,
2005). Stringent control of the PI3K/AKT axis is vital for the
prevention of cellular transformation and tumorigenesis and
impaired regulation of the PI3K/AKT axis is strongly implicated
in oncogenesis (Cheng et al, 2005; Yoeli-Lerner and Toker, 2006).
Regulation is primarily mediated by phosphatase and tensin
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s(PTEN), a tumour suppressor protein encoded on chromosome 10
(Chow and Baker, 2005). While AKT has many intracellular
targets, evidence is accumulating indicating that mammalian target
of rapamycin (mTOR) is a crucial downstream effector of AKT
either in response to growth factors or through ‘loss-of-function’
mutations in PTEN (Altomare and Testa, 2005).
Mammalian target of rapamycin is an evolutionary conserved
multiprotein complex involved in nutrient availability, ribosomal
biogenesis and protein synthesis leading to both cell enlargement
and proliferation. It was first identified in cells as the pharmaco-
logical target of rapamycin, a macrolide antibiotic that inhibits its
inherent serine/threonine kinase activity (Hay and Sonenberg,
2004; Tsang et al, 2007). Two well-characterised downstream
substrates of mTOR are 4E-binding protein 1 (4E-BP1) and the
p70 ribosomal S6 kinase (p70S6K). Growth factor mitogen or
hormone-stimulated mTOR activation mediates the downstream
inhibitory phosphorylation of 4E-BP1 at Ser65 suppressing its
ability to bind and inactivate the translation-initiation factor
eIF4E. Concomitantly, mTOR mediates the activation of p70S6K,
which in turn phosphorylates the 40S ribosomal protein S6 kinase
at Ser235 and Ser236, leading to the promotion of mRNA
translation. Proteins required for cell-cycle progression such as
c-myc and cyclin D1 are activated this way (Averous and Proud,
2006; Mayer and Grummt, 2006).
Previous studies have implicated the AKT/mTOR pathway in a
diverse range of cancers including prostate (Kremer et al, 2006),
lung (Lim et al, 2007), pancreas (Asano et al, 2005), colon (Nozawa
et al, 2007) and oesophagus (Hou et al, 2007). Tumours that
display AKT hyperactivity have shown increased sensitivity to the
growth inhibitory effects of rapamycin (Neshat et al, 2001).
Currently, a number of clinical trials are underway to evaluate the
efficacy of various rapamycin derivatives in the treatment of
malignancy, either as single or combination therapies (Hutson,
2007; Vogelzang and Sternberg, 2007). Encouraging clinical results
have been obtained in RCC to the point that temsirolimus, a
rapamycin derivative, has been approved (FDA) in the treatment
of advanced RCC (Rini et al, 2007).
Caveolin-1 protein was first identified as a substrate for v-src in
transformed fibroblasts, it has wide-ranging effects upon signal
transduction pathways (Williams and Lisanti, 2004). Numerous
in vitro studies have demonstrated that caveolin-1 or a peptide
domain isolated from it functions as a general ‘molecular brake’ by
directly inhibiting the intrinsic kinase activity of numerous growth
factor stimulated signalling moieties that include among others
the receptor tyrosine kinases (EGFR and PDGFR) and their
downstream effectors (Raf, Ras and ERK1/2), nonreceptor kinases
(v-src), PKCa eNOS and G-protein-coupled receptors (Razani et al,
2002; Krajewska and Maslowska, 2004). A number of clinico-
pathological studies have shown a positive correlation between
caveolin-1 overexpression and advanced cancer disease, metatasis
and poor prognosis (for critical review see Williams and Lisanti,
2005).
In 2003, we were the first to reveal that overexpression of
caveolin-1 in localised RCC predicts poor disease-free survival
(Campbell et al, 2003). Subsequently, several laboratories have
independently examined the expression of caveolin-1 (Horiguchi
et al, 2004; Joo et al, 2004; Phuoc et al, 2007) or activated AKT/
mTOR/S6 (Lin et al, 2006; Pantuck et al, 2007; Robb et al, 2007) in
RCC. However, none has yet examined the expression of these
pathways together. We hypothesise that caveolin-1 acts synergis-
tically with the AKT/mTOR pathway in RCC leading to disease
progression, and that this molecularly linked signature represents
a powerful prognostic determinant for identifying subsets of
patients with higher probability of recurrence and metastatic
spread. To address this, we examined the coexpression of caveolin-
1 and phosphorylated mTOR (pmTOR) pathway components in
tumour tissue from 174 RCC patients presenting with localised
disease.
MATERIALS AND METHODS
Patients and RCC tissue microarray
The patient cohort (174 patients) consisted of a consecutive series of
RCCs treated by radical nephrectomy. This series has previously been
reported in detail (Thomas et al, 2003). None of the patients had
received treatment before surgery or had evidence of either lymph
node or distant metastatic disease either before or at surgery.
Histology reports and slides were available in all cases and reviewed
by a pathologist without knowledge of the clinical outcome and
assessed for histological type using the Heidelberg classification
(Kovacs et al, 1997), Fuhrman nuclear grade (Fuhrman et al, 1982),
the presence or absence of any vascular invasion (either microvascular
invasion, renal vein invasion or inferior vena cava invasion) (Griffiths
et al, 2002) and whether or not there was capsular penetration with
cellular invasion of perinephric fat (Thomas et al, 2003).
The median age of the patients was 65 (34–88) years; 119 were
men and 55 women; 119 of the tumours were conventional (clear
cell) carcinomas, 23 were papillary, 5 chromophobe and 27 of the
tumours were unclassified by conventional histology. Complete
clinical follow-up was carried out as previously described (Griffiths
et al, 2002; Campbell et al, 2003), and the following information
extracted from the patients notes date of birth, sex, date of surgery,
date last seen, date of death, cause of death and the date on which
recurrent or metastatic disease was first identified.
A customised tissue microarray (TMA) was constructed from
archived paraffin-embedded tumour samples. A single core,
0.6mm in diameter, was punched from morphologically repre-
sentative peripheral regions of each tumour and precisely arrayed
into recipient paraffin blocks in a specific orientation. Additional
cores were taken from normal renal parenchyma (adjacent to some
of the tumours) and human placenta. Sections (4mm thickness)
were cut from the resulting tumour array blocks onto strongly
adhesive glass slides (Superfrost Plust).
Immunohistochemistry
Immunohistochemical procedures examining for expression of
caveolin-1, pAKT (Ser473), pmTOR (Ser2448), pS6 (Ser235/236)
and p4E-BP1 (Ser65) were carried out using standard procedures
as previously described (Campbell et al, 2003). Primary antibodies
were obtained from New England Biolabs (Herts, UK). Briefly,
TMA sections were deparaffinised, rehydrated and endogenous
peroxidase activity within the rehydrated tissue blocked with a
solution of 3% hydrogen peroxide in methanol for 10min at room
temperature. Antigen retrieval was carried out by boiling in 10mM
sodium citrate solution (pH 6.0) for 10min. The TMA slides were
cooled and equilibrated in Optimaxt wash buffer then incubated
overnight (15h) at 41C with primary antibodies for caveolin-1
(rabbit polyclonal, dilution 1:10), pAKT (mouse monoclonal,
clone 587F11, dilution 1:200), pmTOR (rabbit polyclonal, clone
49F9-IHC specific, dilution 1:10), p-S6 (rabbit polyclonal, dilution
1:100), p4E-BP1 (rabbit polyclonal, dilution 1:25) and VHL
(rabbit polyclonal, dilution 1:10). In all cases, the diluent was 0.6%
BSA in Optimax wash buffer. The sections were then washed
(4 1min), and the appropriate secondary HRP-conjugated anti-
body was applied at a dilution of 1:100 for 1h at room
temperature with immunoreactivity detected with diaminobenzi-
dene (Sigma, Poole, Dorset, UK) as the chromogenic peroxidase
substrate. The slides were counterstained with haematoxylin and
mounted.
Controls and scoring of stained RCC tissue microarray
Evaluation of sections was carried out by consensus over a
conference microscope by a pathologist (DFRG) and a research
associate (LC) without the knowledge of other pathological and
Caveolin-1 and mTOR synergy in RCC
L Campbell et al
932
British Journal of Cancer (2008) 98(5), 931–940 & 2008 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sclinical data as previously described (Campbell et al, 2003).
Expression of each marker was assessed semiquantitatively
according to previously validated criteria that accounted for both
the intensity of immunostain and percentage of tumour cells
involved within each core. Scoring was as follows: (0) no detectable
reaction product (deposit) tumour cells; (1) very light diffuse or
focal light deposit in tumour cell cytoplasm; (2) light diffuse or
moderate focal deposit (but may include very small areas of heavy
deposit); and (3) tumour-containing areas of heavy deposit in
most or all tumour cells.
Tissue cores from human placenta were used as positive control
for pAKT, pmTOR, pS6 and p4E-BP1 immunoreactivity, while
staining of peripheral endothelial cells and fat served as positive
internal control for caveolin-1. Negative controls run in parallel
consisted of TMA sections, where the primary antibody had been
omitted or replaced with the appropriate nonimmune serum.
Data and statistical analyses
Analysis of disease-free survival of patients with tumours showing
different scores of staining for each marker was carried out by
Kaplan–Meier method using log-rank test, where the first
appearance of a metastasis was considered an event. Patients last
seen alive without metastasis or who died due to causes other than
RCC were considered censored at the date last seen or date of death,
respectively. Scores were converted to a binary simple covariate
(positive or negative) by thresholding according to the most
informative split on the Kaplan–Meier using the log-rank statistical
test. For mTOR, AKT and 4E-BP1, a score of 0 was recorded as
negative, and a score of 1, 2 or 3 as positive; for SK6 a score of 0 or 1
was negative, and a score of 2 or 3 positive; for caveolin-1 a score or
0, 1 or 2 was negative and a score of 3 positive. The association of
the positive biomarkers with recognised tumour prognostic
variables (grade, size, vascular invasion, capsular invasion and
tumour type) was examined by cross tabulation and the w
2 test or
Fishers exact test as appropriate; for multiple comparisons the
Holm–Bonferroni corrections are shown.
To test for synergy between caveolin-1 expression and the
activated AKT/mTOR pathway, composite covariates were con-
structed to indicate dysregulation of both caveolin-1 and activated
components of the mTOR pathway. These composite covariates
were determined as positive if caveolin-1 was positive and if the
selected component of the activated AKT/mTOR pathway was also
positive. If either or both were negative the composite covariate
was considered negative.
Multivariate survival analysis was carried out by Cox regression
using the Enter or Forward Stepwise (Likelihood Ratio) function;
with covariates considered as categorical. We had already
determined that the most influential covariates predicting the
disease-free survival of these patients are Fuhrman grade (grades 1
and 2, and grades 3 and 4 are pooled for analysis), any degree of
vascular invasion (histological correlate of stage T2b) and
histological invasion of perinephric tissue (the histological
correlate of stage T2a). When these covariates are taken into
account then tumour size and type had no influence on disease-
free survival (Thomas et al, 2003). To determine if any of the
biomarker covariates had influence on outcome in the multivariate
analysis, each (both simple and composite) was added individually
in turn as an independent covariate to the Cox regression analysis
together with covariates grade, vascular invasion and invasion of
perinephric tissues; time to event being the dependent variable.
We have previously shown that caveolin-1 upregulation is a good
proxy for vascular invasion in multivariate analysis; to determine
if this hold true for the composite covariates the Cox regression
was repeated omitting the covariate vascular invasion.
The statistical package SPSS 11.5 was used for analysis. All tests
were two tailed.
RESULTS
Immunohistochemistry for caveolin-1 and activated
components of the AKT/mTOR pathway in clinically
confined RCC
Caveolin-1 staining was comparable to that previously described
(Campbell et al, 2003) with 28/165 (18%) positive; the distribution
was predominately cytoplasmic, although membranous staining
was observed in some tumours. Analysis of the activation status of
Caveolin-1 pAKT
pS6 p4E-BP1
pmTOR
Positive Negative
Positive Negative Positive Negative
Positive Negative Positive Negative
Figure 1 Representative TMA of clinically confined RCC showing the immunohistochemical expression intensity and pattern of (A) caveolin-1, (B) pAKT,
(C) pmTOR, (D) pS6 and (E) p4E-BP1 for tumours that were typically stratified as either ‘Positive’ or ‘Negative’ (see Materials and Methods).
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sthe AKT/mTOR pathway by the detection of phosphorylated forms
of each of the individual components showed that 129/166 (78%),
39/97 (40%), 23/107 (21%) and 87/146 (46%) of the RCC patients
stained positive for pAKT, pmTOR, pS6 and p4E-BP1, respectively.
The staining pattern of all antibodies was essentially similar in
nature and consisted of granular and uniform cytoplasmic staining
(Figure 1B and E), although some nuclear staining within certain
tumours was observed for pAKT and p4E-BP1.
Cross tabulation of caveolin-1, pAKT, pmTOR, pS6 and p4E-BP1
scores with conventional determinants for RCC is shown in
Table 1. Increased expression levels of caveolin-1 strongly
correlated with tumour grade (P¼0.019), vascular invasion
(P¼0.001) and tumour size (P¼0.003). Phosphorylated mTOR
correlated with tumour size (P¼0.023), capsular invasion
(P¼0.015) and with papillary tumour type (P¼0.006). Of the
other AKT/mTOR components evaluated only pS6 demonstrated a
significant association with tumour grade (P¼0.008). Significantly
increased expression of pAKT, pmTOR and p4E-BP1 was seen in
the papillary RCCs when compared with nonpapillary tumours
(Table 1).
Disease-free survival analysis of caveolin-1 and activated
components of the AKT/mTOR pathway in clinically
confined RCC
Univariate survival analysis of our series showed that those
patients having caveolin-1-positive tumours had significantly
worse prognosis with mean disease-free survival of 3.44 years
compared to 6.20 years in those with negative caveolin-1 tumours
(P¼0.0005); a finding consistent with our previous investigation
(Campbell et al, 2003). Kaplan–Meier plots revealed that the
expression of cytoplasmic pAKT, pmTOR and p4E-BP1 did not
significantly influence disease-free survival. Cumulative survival
curves for pAKT, pmTOR and p4E-BP1 are illustrated in Figure 2
and mean disease-free survival values shown in Table 2. In
contrast, pS6 was the only component of the activated mTOR
pathway that significantly predicted relapse (Figure 2) where the
mean disease-free survival in patients whose primary tumours
expressed pS6 was 3.77 vs 6.11 in those patients whose tumours did
not (P¼0.0096).
Disease-free survival analysis of combined caveolin-1 and
activated components of the AKT/mTOR pathway
We next evaluated by Kaplan–Meier analysis the ability of the
combined expression of caveolin-1 and each of the other
individual downstream-activated components of the AKT/mTOR
pathway to predict relapse using the composite covariates
previously described. Within the combined caveolin-1/pAKT data
set (n¼160), 23/26 (88%) of the caveolin-1-positive tumours also
coexpressed pAKT, while within the combined data sets of
caveolin-1/pmTOR (n¼96), caveolin-1/pS6 (n¼106) and caveo-
lin-1/p4E-BP1 (n¼143) the number of caveolin-1-positive
tumours that coexpressed the selected individual AKT/mTOR
pathway marker was 43, 35 and 52%, respectively (Figure 3).
Patients who had tumours that were positive for both caveolin-1
and pAKT had significantly worse prognosis than patients who
had tumours that expressed neither biomarker or either caveolin-1
or pAKT alone, with a mean disease-free survival of 2.95 vs 6.14
years (Po0.0001). The time to relapse was also substantially
shortened for patients whose tumours coexpressed caveolin-1 and
pS6, with a survival of 1.45 years compared with 5.96 years
(Po0.0001). Likewise, the mean disease-free survival for combined
caveolin-1 and p4E-BP1 expression was 2.07 vs 6.09 years
(Po0.0001). Coexpression of caveolin-1 with activated pmTOR
also significantly reduced the time to disease recurrence with a
mean survival of 3.17 vs 6.28 years (Po0.0001). Collectively, these
data demonstrate that patients who had tumours that coexpressed
caveolin-1 and an activated AKT/mTOR pathway have significantly
shorter recurrence-free survival than those patients who had
Table 1 Relationship of caveolin-1, pAKT, pmTOR, pS6 and p4E-BP1 expression with conventional clinicopathological parameters in clinically confined
RCC
Caveolin-1 (n¼165) pAKT (n¼166) pmTOR (n¼97) pS6 (n¼107) p4E-BP1 (n¼146)
 ve +ve  ve +ve  ve +ve  ve +ve  ve +ve
Grades 1 and 2 102 14 29 89 40 30 64 11 60 45
Grades 3and 4 35 14 8 40 18 9 20 12 19 22
P¼0.01 P¼0.535 P¼0.39 P¼0.008 P¼0.23
Tumour size
o7cm 72 6 20 61 25 26 42 11 36 33
47 c m 6 5 2 2 1 7 6 83 31 3 4 2 1 24 33 4
P¼0.003 P¼0.468 P¼0.023 P¼0.853 P¼0.657
Vascular invasion
( ve) 90 9 24 79 31 26 52 9 45 44
(+ve) 47 19 13 50 27 13 32 14 34 23
P¼0.001 P¼0.689 P¼0.195 P¼0.051 P¼0.283
Capsular invasion
( ve) 118 20 31 109 42 36 71 16 64 56
(+ve) 19 8 6 20 16 3 13 7 15 11
P¼0.06 P¼0.916 P¼0.015 P¼0.103 P¼0.686
Nonpapillary 116 27 37 106 54 28 76 16 77 49
Papillary 21 1 0 23 4 11 8 7 2 18
P¼0.096 P¼0.005* (P¼0.095) P¼0.006* (P¼0.10) P¼0.94 Po0.000* (P¼0.01)
pAKT¼phosphorylated AKT; 4E-BP1¼4E-binding protein 1; p4E-BP1¼phosphorylated 4E-binding protein 1; RCC¼renal cell carcinoma; mTOR¼mammalian target of
rapamycin; pmTOR¼phosphorylated mammalian target of rapamycin. Unequal numbers are due to occasional loss of tumour in array spots on some slides, and, for pmTOR
and pS6, failure to achieve immunocytochemical reactivity with tissue derived from for one of the two laboratories. Associations considered significant at Po¼0.10 after
correction for multiple comparisons are shown with * and with appropriate corrected P-values in parentheses (caveolin results are a confirmation of previous findings –
correction for multiple comparisons is not appropriate).
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components alone (Figure 3 and Table 2B).
Correlation of combined caveolin-1 expression and activated
AKT/mTOR pathway components with established RCC
clinical/pathological covariates using the composite covariates
To address the association of caveolin-1 expression and a
coexisting dysregulated AKT/mTOR pathway with clinico-
pathological covariates, a composite covariate of caveolin-1/AKT
was used. We focused on the biomarker pAKT as an indicator of
AKT/mTOR dysregulation as it is generally considered to be the
critical upstream effector of the downstream mTOR pathway and
represents the central intermediate in our hypothesis that
caveolin-1 sustains AKT activation leading to potentiation of the
mTOR. Further, neither AKT nor caveolin-1 alone is informative
covariates on Cox regression analysis. The caveolin-1/pAKT
composite covariate strongly correlated with tumour grade
(P¼0.044), tumour size (P¼0.008) and vascular invasion
(P¼0.001) (Table 3).
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Figure 2 Kaplan–Meier metastasis-free overall survival estimates of RCC patients with clinically confined disease stratified by ‘Positive’ vs ‘Negative’
expression of (A) caveolin-1, (B) pAKT, (C) pmTOR, (D) pS6 and (E) p4E-BP1.
Table 2 Mean metastasis-free survival of patients with clinically localised renal cell carcinoma
(A) Prognostic indices/univariate model Mean survival (years) 95% CI P-value
Caveolin-1 positive (28) 3.44 2.31–4.58 0.0005*
Caveolin-1 negative (137) 6.20 5.64–6.76
AKT positive (37) 5.52 4.89–6.15 0.1779
AKT negative (129) 5.94 5.04–6.85
mTOR positive (58) 5.82 2.02–7.29 0.103
mTOR negative (39) 5.21 4.29–6.14
S6 positive (23) 3.77 1.27–4.71 0.0096*
S6 negative (84) 6.11 5.41–6.81
4E-BP1 positive (67) 5.09 4.15–6.03 0.077
4E-BP1 negative (79) 5.21 4.29–6.14
(B) Prognostic indices/composite covariate model Mean survival (years) 95% CI P-value
Caveolin-1/AKT positive (23) 2.95 1.74–4.16 o0.0001*
Caveolin-1/AKT negative (137) 6.14 5.57–6.70
Caveolin-1/mTOR positive (7) 3.17 2.01–4.33 o0.0001*
Caveolin-1/mTOR negative (89) 6.28 5.74–6.83
Caveolin-1/S6 positive (7) 1.45 0.00–3.12 o0.0001*
Caveolin-1/S6 negative (99) 5.96 5.57–6.7
Caveolin-1/4E-BP1 positive (13) 2.07 0.6–3.53 o0.0001*
Caveolin-1/4E-BP1 negative (130) 6.09 5.29–6.62
4E-BP1¼4E-binding protein 1; CI¼confidence interval; mTOR¼mammalian target of rapamycin. *Denotes significance Po0.05.
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Using multivariate Cox proportional hazard regression models, we
evaluated whether the coexpression of caveolin-1 and pAKT could
be of prognostic value in the assessment of primary renal tumours.
Covariates included in the model were those that have previously
shown to be influential, that is, tumour grade, capsular invasion
and vascular invasion (Table 4A). The analysis revealed that the
composite covariate of ‘caveolin-1 and pAKT’ was a significant
influential predictor of shortened disease-free survival with a
hazard ratio (HR) of 2.13 (Po0.02), whereas the simple covariates
caveolin-1 and pAKT alone were not. Of note, this predictive value
was higher than that of the powerful and robust prognostic
indicator vascular invasion.
We next repeated the computation with vascular invasion
omitted to evaluate the prognostic significance of the ‘caveolin-1/
pAKT’ covariate for situations where it would not be possible to
examine the presence of vascular invasion. In this model, the
combined positive expression of caveolin-1 and pAKT had an
enhanced HR (2.26; P¼0.009) than when all other prognostic
indices including vascular invasion are incorporated (Table 4B).
Further Cox regression analysis to assess the potential of
combining caveolin-1 expression with other activated components
of the AKT/mTOR pathway is shown in Table 5. Despite the
limited number of valid cases in these data sets, the composite
covariates of both caveolin-1/p4E-BP1 and caveolin-1/S6 were both
powerful and significant predictors of disease reoccurrence with
HR scores of 3.64 (P¼0.001) and 4.69 (P¼0.003), respectively.
DISCUSSION
We have previously shown that increased caveolin-1 serves as a
statistically significant indicator of subsequent metastatic disease
and poor clinical outcome in patients who initially presented with
localised RCC (Campbell et al, 2003). Here, in an extended patient
cohort (174 patients), we show that caveolin-1 expression strongly
correlates with tumour size, tumour grade and the presence of
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Figure 3 Kaplan–Meier metastasis-free overall survival estimates of RCC patients with clinically confined disease according coexpression of caveolin-1
with (A) pAKT, (B) pmTOR, (C) pS6 and (D) p4E-BP1. Patients who coexpressed caveolin-1 and activated components of the AKT/mTOR pathway had
significantly worse prognosis compared with patients whose tumours were negative for either biomarker and/or had single biomarker-positive expression.
Table 3 Correlation of combined caveolin-1 and pAKT (caveolin-1/AKT covariate) positivity with clinical and pathological parameters in patients with
clinically localised renal cell carcinoma
Clinicopathological parameter Caveolin-1 and AKT negative (n¼137) Caveolin-1 and AKT positive (n¼23) P-value
Tumour grades 1 and 2 100 12 0.044*
Tumour grades 3 and 4 37 11 (0.088)
Tumour size o7cm 71 5 0.008*
Tumour size 47cm 66 18 (0.032)
Vascular invasion ( ve) 90 7 0.001*
Vascular invasion (+ve) 47 16 (0.004)
Capsular invasion ( ve) 117 17 0.167
Capsular invasion (+ve) 20 6
Associations considered significant at Po¼0.10 after correction for multiple comparisons are shown with *, with appropriate corrected P-values in parentheses. *Denotes
significance Po0.05.
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svascular invasion. Further, we show that increased caveolin-1 is
associated with reduced disease-free survival, although it is not an
influential covariate in multivariate analysis. Importantly, we go
on to demonstrate that increased expression of caveolin-1 when
combined with an increase in the expression of activated
component(s) of the AKT/mTOR pathway represents a more
powerful prognostic determinant than either caveolin-1 alone or
activated AKT/mTOR component(s) alone, and is highly signifi-
cant in multivariate analysis.
Several reports have recently examined the expression profiles
of various components of the activated AKT/mTOR pathway in
RCC (Lin et al, 2006; Pantuck et al, 2007; Robb et al, 2007).
However, the heterogeneous nature of their patient groups, which
include patients with metastatic disease at presentation, limits the
conclusions that can be drawn. In this current work in clinically
confined RCC where the patients had received no previous
treatment, we found increased pmTOR to demonstrate an
association with tumour size and capsular invasion, suggesting
that activated mTOR is directly linked to the proliferative capacity
of cells within the localised tumour and with tumour invasion into
the immediate surrounding tissue such as the renal capsule. In
contrast pAKT expression, or for that matter p4E-BP1, was not
associated with any histopathological covariates. Only pS6 from
the AKT/mTOR pathway predicted a reduced disease-free survival,
although when cross tabulated with all other known prognostic
determinants pS6 correlated with tumour grade only.
Caveolin-1 has been recognised to potentiate AKT activity in a
variety of model systems. We examined the survival analysis
within our RCC cohort using caveolin-1 combined as a composite
covariate with pAKT (or caveolin-1 combined individually with
other downstream mTOR components). The analysis revealed that
when caveolin-1 is coexpressed with either pAKT, pmTOR, pS6 or
p4E-BP1 within the primary tumour, time to relapse was
significantly reduced compared with when either of the individual
variables were expressed alone. The critical upstream effector of
the mTOR pathway, pAKT, as a composite parameter with
caveolin-1, was selected for further examination against estab-
lished clinicopathological parameters. Despite the frequent over-
expression of activated AKT in primary tumours, its expression
alone in RCC had no significant correlation with histopathological
parameters. However, the composite covariate of ‘caveolin-1 and
activated AKT’ correlated with tumour size, grade and the
presence of vascular invasion in an independent manner and to
a statistically greater extent than when either variable, caveolin-1
or pAKT was analysed alone. We interpret from this that patients
with localised RCC whose tumours are positive for both caveolin-1
and pAKT are likely to have more aggressive and vasoinvasive
disease. Further, this demonstrates that the composite covariate of
caveolin-1 and activated AKT serves as a linked molecular
signature to identify localised tumours that have an increased
propensity to metastasise and provides substantial support for a
hypothesis that caveolin-1 acts synergistically with the AKT/mTOR
pathway in driving disease progression in RCC.
In our previous work (Campbell et al, 2003), we found that
caveolin-1 can be substituted for vascular invasion in a hazard
model for time to recurrence (but not for grade or capsular
invasion), suggesting that its expression is linked to vascular
proliferation. Although the specific mechanism by which caveolin-
1 facilitates cancer progression is still unclear, the strong
correlation with vascular invasion suggests that caveolin-1
contributes to angiogenesis and metastasis. Vascular invasion is
considered to be one of the most important and robust
pathological variables for RCC evaluation (Griffiths et al, 2002;
Gonc¸alves et al, 2004; Dall’Oglio et al, 2007). Therefore, we
constructed a multivariate Cox regression Hazard model to
determine if coexpression of caveolin-1 and pAKT could be a
superior prognosticator in a preoperative assessment scheme. In
such an analysis, we found that the composite covariate ‘caveolin-
1/pAKT’ can be substituted for vascular invasion and indeed
provides for as good a model as vascular invasion in predicting
disease recurrence. This covariate would serve as a readily
determined biomarker for the assessment of tumour recurrence
in clinically confined RCC when histopathological variables cannot
be that easily assessed, for example, in limited biopsy material or
in tumours morcellated in situ (Rabban et al, 2001).
The clinical course of RCC patients that present with localised
disease is difficult to predict, even within subgroups with
Table 4 Multivariate Cox regression hazards model for time to recurrence
(A) Prognostic indices/model including vascular invasion {enter function} (n) HR 95% CI P-value
Grades 1 and 2 (112) 1
Grades 3 and 4 (48) 2.94 1.62–5.36 o0.01*
No capsular invasion present (134) 1
Capsular invasion present (26) 4.22 2.26–7.90 o0.01*
No vascular invasion present (97) 1
Vascular invasion present (63) 1.74 0.88–3.46 0.113
Caveolin/AKT covariate negative (137) 1
Caveolin/AKT covariate positive (23) 2.13 1.15–3.92 o0.02*
(B) Prognostic indices/model excluding vascular invasion {forward conditional} (n) HR 95% CI P-value
Grades 1 and 2 (112) 1
Grades 3 and 4 (48) 3.58 2.05–6.24 o0.001*
No capsular invasion present (134) 1
Capsular invasion present (26) 5.17 2.88–9.29 o0.001*
Caveolin/AKT covariate negative (137) 1
Caveolin/AKT covariate positive (23) 2.26 1.23–4.16 0.009*
CI¼confidence interval; HR¼hazard ratio. *Denotes significance Po0.05.
Table 5 Hazard ratio for time to recurrence of each composite
covariate as calculated by separate multivariate Cox proportional hazards
method using the forward conditional function (including tumour grade,
vascular invasion and presence of caveolin/AKT/mTOR pathway covariate)
Prognostic indices/covariate model (n) HR 95% CI P-value
Caveolin-1/mTOR (7) 2.61 0.99–6.82 0.051
Caveolin-1/4E-BP1 (13) 3.64 1.75–7.54 0.001*
Caveolin-1/S6 (7) 4.69 1.17–12.8 0.003*
4E-BP1¼4E-binding protein 1; CI¼confidence interval; mTOR¼mammalian target
of rapamycin. In all grades and capsular invasions HR remain significant. *Denotes
significance Po0.05.
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sseemingly similar histopathological characteristics. While tumour
biology clearly mirrors that of its histopathological features, it is
suggested that the molecular profile of the tumour more accurately
reflects the biological behaviour of the tumour (Kim et al, 2005).
Therefore, individual biomarkers and linked molecular signatures
such as those identified in our present study can clearly
supplement standard clinical information to provide enhanced
prognostication of RCC patients. To this end, two recent
innovative studies have reported the development of a prognostic
model that incorporates a panel of malignancy-associated
biomarkers (which includes p53, CA9, Ki67, vimentin, CA12,
PTEN and gelosin) with standard clinical parameters and where
the resultant ‘clinical/molecular marker’ model, better predicts
survival of patients with RCC (Kim et al, 2004, 2005). Specifically,
when ranked alongside several conventional RCC staging systems
such as Fuhrman grade, TNM and ECOG-Performance Status (PS),
the integrated ‘clinical/molecular marker’ prognostic model
demonstrated superior prognostic value than either and/or that
afforded by the panel of biomarkers alone. Of note, the ECOG-PS
of our patient cohort was not available, and since this represents
an important model for predicting prognosis of RCC patients (Kim
et al, 2004; Phuoc et al, 2007), its omission should be acknowl-
edged as one limitation to our current Cox proportional hazard
regression modelling. Nevertheless, the composite covariates of
caveolin-1 and activated AKT/mTOR components serve as linked
molecular signatures that clearly identify localised tumours, which
have high invasive capacity and an increased metastatic potential.
Therefore, it is envisaged that their incorporation within similar
combined staging systems for RCC as described above will further
improve the predictive power of such models.
Interestingly, a subset analysis of our RCC cohort revealed that
the expression of caveolin-1 was invariably absent or minimal
within papillary carcinomas; an observation in agreement with
Tamaskar et al (2007). However, high expression of pAKT,
pmTOR, pS6 and p4E-BP1 was evident in these papillary tumours.
Papillary carcinomas represent a subtype that are usually less
vasoinvasive, have reduced metastatic potential and generally have
a good prognosis (Mai et al, 2001; Cheville et al, 2003). Our data
therefore suggest that the presence of an activated AKT/mTOR
pathway alone is not sufficient to impart an aggressive phenotype
but requires caveolin-1, at least in RCC. Consistent with this
finding, in vivo studies show that caveolin-1 knockout mice have a
number of relevant features: (i) when inoculated with the
exogenous melanoma cell line B16-F10, the caveolin-1 knockout
mice show an impaired angiogenic response with reduced tumour
weight, volume, blood vessel infiltration and microvessel density
compared with wild-type littermates (Woodman et al, 2003); and
(ii) when interbred with TRAMP mice that spontaneously develop
advanced prostate cancer and metastatic disease, the resultant
strain that displays inactivation of one or both caveolin-1 alleles
has reduced tumour burden and significant reductions in regional
lymph node and distant organ metastasis (Williams et al, 2005).
An association between the expression of caveolin-1 and AKT
has been previously reported in clinical tumours of the colon (Kim
et al, 2006). Although the relationship on disease progression was
not evaluated, the authors suggested that the presence of caveolin-
1 positively affects AKT activation. Support for the clinical
relevance of caveolin-1/AKT interaction and its impact on the
downstream targets such as mTOR comes from a series of in vitro
experiments that directly demonstrate that caveolin-1 has the
capacity to facilitate AKT signalling in different cell types (Li et al,
2003; Sedding et al, 2005; Zhang et al, 2007). From the perspective
of human cancer progression, Li et al (2003) showed that caveolin-
1 overexpression was able to maintain activated AKT levels in
human prostate cancer cells via inhibition of the tumour
suppressor enzymes PP1 and PP2A, which dephosphorylate AKT
at both Ser473 and The308. Furthermore, the caveolin-1-mediated
increases in AKT activity were sufficient to cause the sequential
phosphorylation of multiple downstream AKT substrates that
included GSK3, FKHR and MDM2 (Li et al, 2003). While the
regulation of the mTOR pathway by AKT was not examined in the
latter study, several lines of investigation provide data to indicate
that this is highly probable and that analogous mechanisms also
occur in RCC given that PP1 has recently shown to have important
growth inhibitory properties in RCC-derived cell lines (Fujimoto
et al, 2006; Hagiwara et al, 2006).
We propose that caveolin-1 may serve as a ‘gatekeeper’ for
activation of the hypoxia-inducible factor (HIF) pathway a
downstream effector molecule of mTOR that accumulates in RCC
in response to the loss of function of VHL and promotes
angiogenesis, vascular invasion and chemoresistance (Patel et al,
2006). Support for this notion is in part provided by other clinical
studies that show that the overexpression of caveolin-1 is
correlated with increased microvessel density within tumours not
only of the kidney (Joo et al, 2004) but also the prostate (Yang
et al, 2007). Therefore, we present a hypothetical model (adapted
from Li et al, 2003) for the coordinated role of caveolin-1 and
the AKT/mTOR pathway in RCC disease progression. In this,
caveolin-1 sustains the activation of the mTOR pathway leading to
HIF-mediated angiogenesis via upstream inhibition of a protein
phosphatase that in turn causes loss of repression of both AKT and
ERK1/2 (see schematic Figure 4). Although we have not yet
examined the correlation between activated ERK1/2 and caveolin-1
in RCC, clearly, the ERK1/2 pathway appears to converge on the
mTOR pathway in RCC, given that specific inhibitors of EGFR
sensitise RCC cell lines to the effects of rapamycin (Costa et al,
2007). That caveolin-1 and mTOR may directly constitute a signal
transduction ‘cassette’ is supported by analysis of the published
peptide sequences of raptor (GenBank accession no. NP065812)
and rictor (GenBank accession no. AAH51729.1), two scaffold
proteins essential for mTOR function that serve to bring mTOR
substrates into close proximity to its catalytic domain. We are able
to identify that both raptor and rictor contain a recognised
consensus caveolin-1-binding motif (FxxxxFxxF, where F is an
aromatic residue and x is any amino acid) (Couet et al, 1997).
Within raptor, the main accessory molecule of the rapamycin-
sensitive mTOR pathway can be identified by the motif L-xxxx-F-
xx-F located between amino acids 201–209. This, although not a
bone fide caveolin-binding motif, has been shown to be critical
in mediating a functional association between caveolin-1 and
Caveolin-1
Activation
Inhibition
mTOR
Raptor Rictor
AKT
PP2A/PP1A
ERK
SK6/S6 4E-BP1
HIF: Translation and Angiogenesis
Figure 4 Schematic of the putative caveolin-1/AKT/mTOR axis in RCC.
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sG-protein-coupled receptor kinases (Carman et al, 1999). The
corresponding caveolin-binding domain in rictor, the central
scaffold protein of the rapamycin-insensitive pathway is present
between amino acids 889–897(FQDIPYSDW).
In conclusion, the coexpression of caveolin-1 and activated
components of the AKT/mTOR pathway represents a ‘linked
molecular signature’ that identifies patients with localised RCC
that are at high risk of developing metastatic disease that warrants
greater postoperative surveillance. Evaluation of the expression
status of both caveolin-1 and mTOR pathway components in these
tumours may help predict tumour response to novel pathway-
specific therapies, hence allowing appropriate selection of treat-
ment for individual patients. In addition, these current results also
further underline the importance of caveolin-1 in RCC progression
and its validity as a future therapeutic target for advanced RCC.
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